Tag: FDA biosimilars
Jan, 28 2026
FDA Listing for Biosimilars: How They Are Evaluated and Approved
The FDA doesn't rate biosimilars like generics-they undergo a rigorous scientific review to prove they're highly similar to the original biologic. Learn how approval works, what 'interchangeable' means, and why biosimilars are changing access to expensive treatments.
Jan, 14 2026
Lot-to-Lot Variability in Biologics and Biosimilars: What You Need to Know
Lot-to-lot variability is a natural part of biologics and biosimilars due to their complex manufacturing. Unlike generics, these drugs aren't identical between batches - but they're rigorously tested to ensure safety and effectiveness.